Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Industry News

Latest generation DES: ANGIOLITE trial 24-month outcomes revealed at EuroPCR 2019 the non-inferiority of angiolite vs the gold standard EES

May 23, 2019

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Caitlin E. Cox

May 23, 2019

News Conference News EuroPCR 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

Caitlin E. Cox

May 21, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

Shelley Wood

March 01, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

News Daily News

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Todd Neale

January 15, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Ken Kozuma About MODEL U-SES: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

September 27, 2019

Advertisement

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Latest generation DES: ANGIOLITE trial 24-month outcomes revealed at EuroPCR 2019 the non-inferiority of angiolite vs the gold standard EES

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

TCTMD’s Top 10 Most Popular Stories for February 2019

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Dr. C. Michael Gibson Talks With Dr. Ken Kozuma About MODEL U-SES: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content